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Role of Plasmalogens in the Enhanced Resistance of LDL to
Copper-Induced Oxidation After LDL Apheresis
Daniela Hahnel, Joachim Thiery, Thorolf Brosche, Bernd Engelmann
Abstract—Extracorporeal reduction of plasma low density lipoproteins (LDLs) by LDL apheresis was shown to attenuate
the proatherogenic influences of LDL, such as impairment of vasodilation and increased monocyte adhesion to the
endothelium. In 16 patients with familial hypercholesterolemia, we analyzed whether LDL apheresis by the heparin
precipitation procedure affected the oxidative resistance of LDL. Plasma LDL cholesterol concentrations were reduced
by 65% after the apheresis. The lag time of copper-mediated LDL oxidation was increased from 103 to 117 minutes
(P,0.0005). The LDL contents of a-tocopherol and b-carotene, as well as the ratio of monounsaturated to
polyunsaturated fatty acids in LDL, were not altered. However, the LDL apheresis induced a 15% increase in the LDL
contents of plasmalogen phospholipids (P,0.0005), a class of ether phospholipids that were recently shown to prevent
lipid oxidation. The phosphatidylcholine (PC) to lysoPC ratio was elevated by 16% after the apheresis (P,0.0005). The
percent increase in LDL plasmalogen phospholipids showed a close association with the increased lag time after
apheresis (P,0.0005). The LDL plasmalogen contents of the blood samples from patients and from normolipidemic
donors were also positively related to the lag time (P,0.005). In vitro loading of LDL with plasmalogen phospholipids
resulted in a prolongation of the lag time and an increase in the PC/lysoPC ratio. In conclusion, the rapid rise in LDL
contents of plasmalogen phospholipids most probably causes the increase in lag time after LDL apheresis. Plasmalogens
appear to play an important role in the oxidation resistance of LDL in vivo. (Arterioscler Thromb Vasc Biol.
1999;19:2431-2438.)
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T
he hypothesis that oxidized LDLs play a relevant role in
the development and maintenance of atherosclerosis1,2 is
based on considerable experimental evidence. In vitro–oxi-
dized LDL reproduces many features characteristic of athero-
sclerotic vascular damage, such as increased adhesion of
monocytes to the endothelium,3 transformation of macro-
phages into foam cells,4 and impaired endothelium-dependent
vasorelaxation.5 Oxidized LDL was shown to be present in
the atherosclerotic plaque.6 Furthermore, the LDL isolated
from the plasma of patients with atherosclerosis exhibited an
enhanced susceptibility toward oxidation in most studies.7–9
Extracorporeal LDL apheresis, the removal of the greater
part of plasma LDL particles from the circulation, is currently
used for the treatment of patients with severe hypercholes-
terolemia.10 The efficacy of this treatment in preventing fatal
and nonfatal cardiovascular events has been demonstrated.11
Furthermore, LDL apheresis was shown to ameliorate the
impaired endothelium-dependent vasorelaxation.12 The pro-
cedure also led to diminished expression of endothelial
adhesion molecules.13,14 Thus, typical proatherogenic conse-
quences of oxidized LDL are attenuated after therapeutic
reduction of LDL. Although removal of the particles per se
might partially account for these effects, changes in the
oxidizability of the LDL induced by LDL apheresis could
also be relevant.
In the present investigation, the oxidative resistance of
copper-oxidized LDL was found to be enhanced after aphere-
sis, in accordance with recent work.15,16 In view of these
findings, we attempted to gain insight into the mechanism
responsible for the increased oxidation resistance after the
LDL apheresis. Several chemical factors are known to influ-
ence the susceptibility of LDL toward copper-mediated oxi-
dation. These include a-tocopherol,17–19 the degree of unsat-
uration of the LDL-based fatty acids,20 b-carotene,21
ubiquinol-10,22,23 and plasmalogen phospholipids.24,25 The
results indicated that the enhanced oxidation resistance after
LDL apheresis was specifically related to an increase in LDL
plasmalogens.
Methods
Subjects
Sixteen patients with familial hypercholesterolemia (FH; 10 men and
6 women; mean6SD age 4966 years; range 42 to 61 years) who had
already been treated biweekly by LDL apheresis for at least 14
months were included in the study. All patients had angiographically
assessed coronary heart disease and were concomitantly treated with
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2431hydroxymethylglutaryl CoA-reductase inhibitors and aspirin. Six of
the patients (5 men, 1 woman) were concomitantly supplemented
with vitamin E (400 IU/d). The supplementation had been started at
least 8 weeks before the study. In some experiments, the LDL
particles from 10 normolipidemic donors (8 men and 2 women; mean
age 49610 years; range 39 to 64 years) were also analyzed. Fasting
blood samples were drawn into EDTA-coated tubes before or after
apheresis, or, in some experiments, 48 hours after apheresis. The
LDLs were isolated by ultracentrifugation or heparin precipitation
(as indicated), the particles being stored for ,30 minutes at 4°C
before the start of the analyses. Informed consent was obtained from
all patients and volunteers. The studies were carried out according to
the principles of the Declaration of Helsinki.
Lipoprotein Analyses
Plasma cholesterol and triglycerides were measured using enzymatic test
kits from Boehringer Mannheim. Plasma LDL cholesterol was quantified
by a direct precipitation procedure (Immuno). HDL cholesterol was deter-
mined enzymatically (Boehringer Mannheim) after initial precipitation of
apo B–containing lipoproteins with phosphotungstate/MgCl2.
Procedure of the LDL Apheresis
LDL apheresis was performed using the HELP procedure (Heparin-
induced Extracorporeal LDL Precipitation; Plasmat-Secura, B.
Braun).26 In brief, plasma obtained by filtration of whole blood (70
mL/min) through a plasma separator was continuously mixed with an
acetate buffer containing heparin. At the resulting pH of 5.12, LDL,
lipoprotein(a), and fibrinogen were precipitated. After removal of the
precipitated heparin complex by filtration, excess heparin was
adsorbed by an anion-exchange column, and the clear, plasma filtrate
was subjected to bicarbonate dialysis to restore plasma volume as
well as the physiological pH. The plasma thus obtained was returned
together with blood cells to the patient. During a single HELP
apheresis, 2.5 to3Lo fplasma was treated. The duration of the
treatment was 2 to 3 hours.
LDL Susceptibility to Oxidation (Lag Time) and
Analysis of TBARS
LDL was prepared within 10 hours after blood collection by
sequential ultracentrifugation. Blood was drawn into tubes contain-
ing EDTA (1 mg/mL). Plasma was separated from the blood cells by
a 10-minute centrifugation. The plasma with a density of 1.02 g/mL
was centrifuged for 4 hours at 340 000g in polycarbonate tubes in a
TL-100 ultracentrifuge with a TLA-100.1 rotor (Beckman Instru-
ments). After recovery, the infranatant was adjusted to a density of
1.063 g/mL with NaCl and centrifuged for 4 hours at 340 000g. The
supernatant solution containing the LDL was freed from the EDTA
by passage through desalting columns (Econo Pac IODG, Bio-Rad
Laboratories). The particles were resuspended in O2-saturated PBS
(10 mmol/L, pH 7.4) at a concentration of 0.26 mmol cholesterol per
liter. CuCl2 (final concentration 1.67 nmol/mL) was added from a
freshly prepared stock solution. The suspension was incubated at
30°C, and the absorbance at 234 nm was monitored at 5-minute
intervals for 4 hours to follow the formation of conjugated dienes.
The lag time was determined as the intercept of the baseline and the
slope of the absorbance curve during the propagation phase.9
Thiobarbituric acid–reactive substances (TBARS) were deter-
mined according to Wallin et al,27 with some modifications. In brief,
to tubes containing 200 mL of 50% trichloroacetic acid, 75 mLo f
1.3% TBA (in 0.3% NaOH, wt/vol) was added. The tubes were
heated for 60 minutes at 90°C and then cooled in ice water. After
centrifugation, 200 mL of the supernatant was transferred to a
96-well plate, and the differences between the absorbances at 530 nm
and those at 630 nm were determined. The values thus obtained were
compared with those of a standard curve of malondialdehyde
equivalents, generated by hydrolysis of 1,1,3,39-tetraethoxypropane.
LDL Contents of a-Tocopherol and b-Carotene
LDL was isolated from EDTA-plasma by precipitation with heparin-
acetate buffer (0.3 mol/L sodium acetate, 100 IU/mL sodium
heparinate, pH 4.85) and resuspended in a Tris buffer containing
(in mmol/L) 154 NaCl, 3 NaN3, and 1 EDTA and 10 g/L albumin
(pH 7.4). The a-tocopherol contents were measured fluorometrically
by high-performance liquid chromatography in hexane extracts of
the LDL suspensions as described previously.9,28 When the LDL
particles were isolated by ultracentrifugation, the LDL contents of
a-tocopherol agreed within 5.361.4% with those determined in
particles prepared by precipitation with the heparin-acetate buffer.
The contents of b-carotene were determined in the same extracts by
separation using reversed-phase high-performance liquid chromatog-
raphy and subsequent spectrophotometric detection at 450 nm
(retention time515.8 minutes) according to procedures described in
Reference 29.
LDL Contents of Plasmalogen and
Ester Phospholipids
LDL was recovered by precipitation with heparin-acetate buffer as
described above. LDL lipids were extracted according to Bligh and
Dyer30 by using chloroform containing 50 mg/L BHT. Phospholipids
were separated by 2-dimensional thin-layer chromatography on DC
60 plates (Merck) by using the solvents proposed by Broekhuyse.31
In some of the samples, the percentages of the major LDL-associated
phospholipids (phosphatidylcholine [PC], sphingomyelin, lysoPC,
phosphatidylethanolamine [PE], and phosphatidylinositol) were sub-
sequently determined by phosphate analysis.32 In other samples, the
spots corresponding to PC and PE were scraped from the plate and
the phospholipids eluted by addition of chloroform/methanol (1:4,
vol/vol). The extraction was repeated twice. The phospholipids were
applied to small thin-layer chromatography plates (10310 cm),
which were exposed for 3 minutes to HCl fumes (37% in water).
After being dried, the plates were developed in chloroform/metha-
nol/acetic acid/water (90:40:12:2, vol/vol/vol/vol). The phosphate
contents of the spots corresponding to lysoPC and lysoPE, which
reflected the amounts of plasmenylcholine and plasmenylethano-
lamine, respectively, were measured.32 When 2 LDL samples ob-
tained at the same time from the same donor were analyzed
separately from the start of the analysis, the determinations of the
plasmalogen phospholipids agreed within 2.861.3%.
Fast Protein Liquid Chromatography
Gel filtration analysis of plasma was performed by means of a
Superose 6 column (Pharmacia). Plasma (100 mL) was injected onto
the column and eluted with a buffer containing (in mmol/L) 150
NaCl, 10 Na2HPO4, and 0.1 EDTA (pH 7.5) at a flow rate of 50
mL/min. Forty fractions of 50 mL were collected: fractions 15
through 19, VLDL and chylomicrons; fractions 20 through 26, IDL
and LDL; and fractions 27 through 33, HDL. Cholesterol and
triglyceride determinations were performed as described above.
Determinations of Fatty Acids
After precipitation of the LDL with the heparin-acetate buffer and
extraction of LDL lipids (as per Reference 30 with chloroform
containing 50 mg/L BHT), fatty acid methyl esters were generated
by addition of BF3-methanol.33 Subsequently, the fatty acid methyl
esters were separated using a gas chromatograph (Hewlett-Packard
HP-5880 A) equipped with a flame ionization detector.
In Vitro Loading of LDL With Plasmalogen
Phospholipids and a-Tocopherol
Fresh venous blood from normolipidemic donors was drawn into
tubes containing EDTA, and plasma was recovered by centrifuga-
tion. For the in vitro loading of LDL with brain plasmenylethano-
lamine (isolated as described previously in Reference 34), small,
unilamellar vesicles were prepared. Aliquots (0.4, 0.7, and 1 mmol)
of either brain plasmenylethanolamine or diacyl PE (16:0/18:2 PE)
were dissolved together with 1.2, 2.1, and 3 mmol, respectively, of
egg PC in 100 mL of ethanol (“low, medium, and high enrichment”;
cf Table 3). The solutions were added very slowly with stirring to 10
mL of plasma, and the suspensions were incubated at 37°C under
argon for 6 hours. The amount of plasmenylethanolamine and diacyl
PE additionally present in the particles after this incubation period
was comparable. Subsequently, LDL was prepared by ultracentrifu-
gation.35 The amount of LDL-associated protein was determined by
2432 Arterioscler Thromb Vasc Biol. October 1999using the Bradford procedure.36 Before the start of the oxidation with
copper or 2,29-azobis-2-amidinopropane hydrochloride (AAPH),
LDL was dialyzed at 4°C under argon against PBS buffer for 12
hours.
Statistics
Statistical differences induced by the LDL apheresis were evaluated
by repeated-measures ANOVA. Where appropriate, the Wilcoxon
signed-rank test was employed. In other cases, the differences were
analyzed by 1-way ANOVA (comparisons between patients with and
without vitamin E supplementation; effects of in vitro loading of
LDL with plasmalogens). All values are given as mean6SD.
Results
Increased Lag Time After Apheresis
After a single LDL apheresis, total plasma and LDL choles-
terol contents were reduced by 47% and 65%, respectively, in
the 16 patients with FH (Table 1). Plasma HDL cholesterol
contents remained unaffected by the procedure. The lag time
of copper-mediated conjugated-diene formation was deter-
mined in LDL particles isolated before and after the aphere-
sis. In 15 of the 16 patients analyzed, the lag time was
prolonged after the apheresis, while in 1 patient it was
unchanged (Figure 1, upper panel). The mean lag time value
as determined before apheresis was 52% higher in the
patients supplemented with vitamin E compared with that in
patients without vitamin E supplementation (lower panel of
Figure 1). After the apheresis, the lag time was increased by
16% and 15% in patients with and without vitamin E
supplementation, respectively (Figure 1, lower panel). When
all 16 patients were included in the analysis, the median of the
lag time values was found to be increased by 14% (from
103.1 before to 117.2 minutes after, P,0.0005). The LDL
particles isolated before and after the procedure exhibited no
change in their electrophoretic mobility. Furthermore, no
TBARS could be detected in the lipoprotein samples at the 2
time points. When the particles were analyzed by fast protein
liquid chromatography, the size of the LDL was found to be
unaltered after apheresis.
Two days after the apheresis, the duration of the lag time
reapproached the preapheresis values (98.5612.3 minutes
before versus 114.869.7 minutes after; P,0.05 after versus
before; 48 hours after apheresis: 106.7611.6 minutes; mean
values of 6 patients with FH). In patients with FH treated by
a different procedure of LDL apheresis (immunoabsorption
with the use of apo B antibodies37), we also observed an
increase in the lag time after a single apheresis (performed by
the heparin precipitation procedure; not shown). The possi-
bility was considered that the anticoagulation with heparin
during the extracorporeal procedure might have contributed
to the increased lag time after the apheresis. Accordingly,
5000 IU of heparin was given intravenously to 3 normolipi-
demic donors as well as to 3 patients with FH (without
vitamin E supplementation). The lag time of the isolated LDL
oxidized with copper (1.67 nmol/mL) was not altered by the
heparin administration (normolipidemic individuals:
99.8618.1 minutes before versus 100.7612.7 minutes 1 hour
after heparin; patients with FH: 82.5612.3 minutes before
versus 79.6610.2 minutes after heparin).
Elevation of LDL Plasmalogen Phospholipids
After Apheresis
The oxidative resistance of LDL is governed by several
factors, among which the LDL-associated antioxidants are of
particular importance.19 a-Tocopherol is considered to be 1 of
the main LDL-based antioxidants. The a-tocopherol contents
of the LDL from patients supplemented with vitamin E were
2.3-fold higher than those of the patients without vitamin E
supplementation (Table 2). The LDL contents of a-tocoph-
erol were not altered by the apheresis in the 2 groups of
patients with FH (Table 2). Furthermore, the LDL contents of
b-carotene as well as the ratio of monounsaturated to poly-
unsaturated fatty acids of the particles were also not signifi-
cantly modified.
TABLE 1. Plasma Cholesterol, LDL-Cholesterol, and HDL
Cholesterol Concentrations Before and After LDL Apheresis in
16 Patients With FH
Total Cholesterol LDL Cholesterol HDL Cholesterol
Before 5.760.9 3.960.6 1.160.2
After 3.060.7* 1.460.4* 1.160.2
Mean values are in mmol/L plasma.
*P,0.0005 after vs before.
Figure 1. Effect of LDL apheresis on the lag time of conjugated-
diene formation in copper-oxidized LDL. Blood was obtained
from 16 patients with FH before and after a single LDL aphere-
sis, and the LDL particles were isolated. The LDL was oxidized
with CuCl2 (1.67 nmol/mL), and the duration of the lag time was
calculated as described in Methods. Upper panel, Lag time val-
ues of individual patients:  patients without vitamin E supple-
mentation; F patients receiving vitamin E (400 IU/d). Lower
panel, Mean values of the data shown in the upper panel. pre
indicates before apheresis; post, after apheresis. Columns with
horizontal bars, patients without vitamin E supplementation; col-
umns with vertical bars, patients receiving vitamin E. *P,0.05,
**P,0.0005 vs pre.
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phospholipids, in particular a reduction in LDL PC and a
concomitant increase of lysoPC, its degradation product.38,39
The PC/lysoPC ratio of the particles was increased by 15%
(patients without vitamin E supplementation) and 16% (with
vitamin E supplementation) subsequent to the procedure
(Table 2). After inclusion of all 16 patients into the analysis,
the mean PC/lysoPC ratio was found to be elevated by 16%
(from 20.963.3 before to 24.263.9 after apheresis,
P,0.0001).
Recent work indicates that plasmalogen phospholipids may
play a relevant role in the oxidation resistance of LDL in
vitro.24,25 The preapheresis values for the LDL-associated
plasmalogens were 2.6-fold higher in patients with vitamin E
supplementation compared with patients not supplemented
with vitamin E (Table 2). After LDL apheresis, the plasmalo-
gen contents were increased by 14% and 13% in patients
without and with vitamin E supplementation, respectively
(Table 2). When all patients were included in the analysis, the
median of the LDL plasmalogen contents was elevated by
15% after the apheresis (from 20.9 before to 24.0 mmol/mmol
of LDL cholesterol after apheresis, P,0.005).
Relations Between Lag Time and LDL
Plasmalogen Contents
In view of these results, we analyzed whether the increase in
LDL plasmalogens after apheresis was related to the prolon-
gation in the lag time. As shown in Figure 2, there was a
positive correlation between the percent elevation of the LDL
plasmalogen contents induced by the apheresis and the degree
of prolongation of the lag time. The positive associations
were also noted when the 2 groups of patients without and
with vitamin E supplementation were analyzed separately
(without vitamin E: r50.66, P,0.05; with vitamin E:
r50.92, P,0.005). The extent of increase in the lag time after
apheresis was not related to the percent elevation of the
PC/lysoPC ratio (r50.06, NS).
The LDL contents of a-tocopherol and of plasmalogen
phospholipids as measured before apheresis in patients with
FH and those of normolipidemic donors were compared with
their lag time values. In the total group of 20 individuals thus
evaluated, the LDL a-tocopherol contents exhibited a weak,
positive association with the lag time values (Figure 3, upper
panel). The plasmalogen contents showed a stronger relation
to the lag time values in the same individuals (Figure 3, lower
panel). The PC/lysoPC ratios as determined at the same time
point in the same donors did not exhibit a significant relation
to the duration of the lag time (r50.18). When the preaphere-
sis values of all patients with FH and of the normolipidemic
individuals were compared with the duration of the lag time,
positive correlations were obtained (a-tocopherol versus lag
time: r50.79, P,0.0001; plasmalogen phospholipids versus
lag time: r50.83, P,0.0001; n526).
TABLE 2. Effect of LDL Apheresis on LDL Oxidation Parameters
Before After
Patients without vitamin E supplementation
a-Tocopherol, mmol/mmol LDL cholesterol 4.860.9 4.061.1
b-Carotene, mmol/mmol LDL cholesterol 0.2860.13 0.2460.09
Monounsaturated/polyunsaturated 0.4260.06 0.4460.06
PC/lysoPC 19.562.9 22.463.4†
Plasmalogen phospholipids,
mmol/mmol LDL cholesterol
17.163.9 19.565.0†
Patients with vitamin E supplementation
a-Tocopherol, mmol/mmol LDL cholesterol 11.263.7* 10.864.4
PC/lysoPC 23.362.5 27.162.7†
Plasmalogen phospholipids,
mmol/mmol LDL cholesterol
44.666.0* 50.5611.0
PC indicates phosphatidylcholine; lysoPC, lysophosphatidylcholine. Contents
of a-tocopherol, b-carotene, and plasmalogen phospholipids were determined
as described in Methods. The ratio of monounsaturated to polyunsaturated fatty
acids was calculated by dividing the sum of the weight percentages of
monounsaturated fatty acids by the sum of the weight percentages of
polyunsaturated fatty acids. The monounsaturated fatty acids included
16;1(n27), 18;1(n27), 18;1(n29), 20;1(n29), and 24;1(n29). The follow-
ing polyunsaturated fatty acids were analyzed: 18;2(n26), 20;2(n29),
18;3(n26), 18;3(n23), 20;3(n26), 20;3(n29), 20;4(n26), 20;5(n23),
22;5(n23), 22;5(n26), and 22;6(n23). Percentages of PC and of lysoPC
were determined after 2-dimensional thin-layer chromatography and subse-
quent phosphate determination as described in Methods. The PC to lysoPC ratio
was calculated by dividing the percentage of PC by the percentage of lysoPC.
Mean values are for patients with FH not receiving vitamin E (n510) or being
supplemented with the antioxidant (n56).
*P,0.0005 vs patients without vitamin E supplementation.
†P,0.0005 vs same parameter before supplementation.
Figure 2. Relation between the percent changes in lag time and
in LDL plasmalogen contents after LDL apheresis. In the 16
patients with FH, the LDL contents of plasmalogen phospholip-
ids (plasmenylethanolamine plus plasmenylcholine) were mea-
sured before and after LDL apheresis as described in Methods
and the percent changes calculated. From the data of Figure 1,
the percent modiﬁcations in lag time values were determined. 
Patients without vitamin E supplementation; F patients receiving
vitamin E (400 IU/d).
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Plasmalogen Phospholipids
To evaluate whether changes in the LDL contents of the
plasmalogen phospholipids could be responsible for the
variations in LDL oxidation resistance, LDL particles were
enriched in vitro with 3 different quantities of plasmenyleth-
anolamine and, as a control, with similar amounts of diacyl
PE (low, medium, and high enrichment). Thereby the total
plasmalogen contents (plasmenylcholine plus plasmenyleth-
anolamine) were increased by 17%, 31%, and 46% compared
with the respective diacyl PE-loaded particles (Table 3). The
procedure did not alter the a-tocopherol contents of the
particles (not shown).
The duration of the lag time as well as the changes in the
PC/lysoPC ratios induced by copper oxidation in the diacyl
PE-enriched particles were comparable to those observed in
control LDL (without any enrichment; Table 3). The lag time
of conjugated-diene formation in copper-oxidized particles
was prolonged by 10%, 13%, and 26%, respectively, in LDL
particles in vitro-loaded with the 3 different amounts of
plasmenylethanolamine compared with the respective li-
poproteins enriched with diacyl PE (Table 3). The LDL
particles from 2 patients with FH (not receiving vitamin E)
were in vitro–loaded with either plasmenylethanolamine or
diacyl PE under conditions corresponding to the low plas-
malogen enrichment of Table 3. The total LDL plasmalogen
contents thus obtained were 21.1 (enrichment with diacyl PE)
and 24.9 mmol/mmol of LDL cholesterol (enrichment with
plasmenylethanolamine). Concomitantly, the lag time of LDL
oxidized with copper (1.67 nmol/mL) was increased by 11%,
from 85.467.2 (diacyl PE loading) to 94.662.3 (plasme-
nylethanolamine loading; means of 4 determinations,
P,0.05).
After a 2- and 4-hour oxidation of diacyl PE-enriched LDL
with copper, the PC/lysoPC ratios of LDL were reduced by
31% to 38% and by 63% to 68%, respectively (Table 3). The
copper-induced decrease of the PC/lysoPC ratio was attenu-
ated by 36% (2-hour incubation) and 20% (4-hour incuba-
tion) in particles with low plasmalogen enrichment compared
with the respective particles loaded with diacyl PE. The same
plasmalogen-enriched LDL particles were also subjected
to oxidation with the peroxyl radical generator AAPH (2
mmol/mL). The decrease in the PC/lysoPC ratio elicited by
AAPH after 2 and 4 hours of incubation was comparable to
that induced by copper (Table 3). The AAPH-mediated
reductions of the ratio were lowered by 35% (2 hours) and by
23% (4 hours) as a consequence of the plasmalogen enrich-
ment (compared with the LDL loading with diacyl PE).
In LDLs with medium plasmalogen enrichment, the
copper-mediated reduction of the PC/lysoPC ratio was pre-
vented by 28% (2-hour incubation) and 32% (4-hour incuba-
tion) in relation to the respective control particles containing
additional diacyl PE. After enrichment with the highest
amount of plasmenylethanolamine, the oxidative degradation
of PC was reduced by 43% and 39% after 2 and 4 hours of
incubation of LDL with copper compared with the respective
controls (Table 3).
Discussion
In the present investigation, we observed rapid changes in the
oxidizability of the LDL particles after LDL apheresis in
patients with FH. After the extracorporeal reduction of LDL,
the resistance of LDL to copper-induced oxidation was
enhanced, as indicated by a prolongation in the lag time of
conjugated-diene formation. Concomitantly, the LDL con-
tents of plasmalogen phospholipids were increased after
apheresis, their elevation being most likely responsible for the
strengthening of the oxidation resistance of the particles.
The reduced susceptibility of LDL toward copper oxida-
tion observed in the present study after apheresis by the
heparin precipitation method is in line with results of recent
investigations performed with other procedures.15,16 Although
relatively limited, the increase in lag time elicited by the
apheresis might well be of physiopathologic relevance. In-
deed, the previously observed differences in the lag time
between healthy individuals and patients with coronary ath-
erosclerosis and hyperlipidemia are mostly in a comparable
percent range as those induced by the apheresis.7–9
The oxidation resistance of LDL was determined in the
present study by the use of a relatively high concentration of
copper (1.67 nmol/mL). Previous work shows that at this and
Figure 3. Relations between the lag time values and the LDL
contents of a-tocopherol and plasmalogens. The LDL lag time
values as well as the plasmalogen and a-tocopherol contents of
10 patients with FH (without vitamin E, measured before
apheresis) and of 10 normolipidemic donors were determined
concomitantly. Upper panel, Relations between the LDL con-
tents of a-tocopherol and the duration of the lag time. Lower
panel, Relations between the LDL contents of plasmalogen
phospholipids and the lag time. , Patients with FH (without
vitamin E supplementation); , normolipidemic donors.
Hahnel et al Plasmalogens and Oxidative Resistance of LDL 2435higher concentrations of the metal ion, the length of the lag
time is inversely related to the copper concentration.19,40
Although several findings indicate a relevant role for copper
as a major oxidant under in vivo conditions (see, for example,
References 41 through 43), the importance of the metal ion is
still a matter of debate.44 Nevertheless, the increase in LDL
plasmalogen contents after LDL apheresis is expected to also
enhance the resistance of LDL to other oxidants. This can be
deduced from earlier results indicating a comparable reduc-
tion of LDL-associated plasmalogens after copper- and per-
oxyl radical–mediated oxidation.24 Furthermore, plasmalo-
gens are able to protect polyunsaturated fatty acids against
oxidation by peroxyl radicals.34 In addition, experimental
increases in LDL plasmalogen contents comparable to those
elicited by the LDL apheresis prevented the degradation of
LDL PC induced by peroxyl radicals (Table 3).
To identify the factor(s) responsible for the augmented lag
time after apheresis, several possibilities were considered.
a-Tocopherol is a major determinant of the oxidation resis-
tance of LDL.17–19 However, the LDL contents of a-tocoph-
erol were unchanged after the procedure (Table 2). Also, the
level of other factors potentially influencing the susceptibility
of LDL toward copper oxidation, such as the ratio of
monounsaturated to polyunsaturated fatty acids22 or the
b-carotene contents,23 were not significantly altered by the
apheresis.
Plasmalogen phospholipids were recently shown to con-
tribute to the oxidation resistance of LDL.24,25 Further work
indicates that plasmalogens reduce the oxidation of lipids in
cells,45 liposomes, and micelles,34,46 as elicited by various
oxidants, including the metals copper and iron, peroxyl
radicals, and photooxidation. Their inhibitory effects on lipid
oxidation are apparently related to a direct reaction of the
plasmalogen-specific enol-ether double bond with the oxi-
dants. It was recently shown that 1 enol-ether double bond is
able to scavenge 2 peroxyl radicals.34 In addition, the enol-
ether appears to possess a high affinity toward interaction
with copper ions, as determined by the use of nuclear
magnetic resonance techniques in detergent micelles (D.H. et
al, unpublished observations, 1999).
In the patients with FH analyzed in the present study, the
percent increase in the LDL contents of total plasmalogen
phospholipids (plasmenylethanolamine plus plasmenylcho-
line) exhibited a strong, positive relation to the prolongation
of the lag time (Figure 2). When the preapheresis values for
the LDL plasmalogen contents of the patients and those of
normolipidemic donors were compared with the duration of
the lag time, a close positive association between both
parameters was again noted (Figure 3). The correlation
between the a-tocopherol contents of LDL and the lag time
was less pronounced in individuals not supplemented with
vitamin E but became stronger after inclusion of the patients
with vitamin E supplementation, in accordance with earlier
data.19,47 Future studies are needed to evaluate whether the
association between the plasmalogen contents and the oxida-
tion resistance of LDL is also evident in larger populations of
individuals. When LDL particles were loaded in vitro with
plasmenylethanolamine (“low plasmalogen enrichment”; Ta-
ble 3), comparable percent changes in the lag time of
copper-oxidized LDL were obtained as by the increase in
plasmalogen contents induced by the LDL apheresis. Thus,
the elevated LDL plasmalogen contents are most likely
responsible for the prolongation in the lag time values
observed after LDL apheresis.
The reasons for the elevation in LDL plasmalogen contents
after the apheresis are unknown at present. Plasmalogens
were shown to be rapidly exchanged between lipid donors
and erythrocytes.48 The plasmalogen pool of red blood cells,
TABLE 3. Lag Time Values and PC/LysoPC Ratios in Copper-Oxidized LDL After In Vitro Enrichment With
Plasmalogen Phospholipids
LDL Plasmalogen Content,
mmol/mmol LDL Cholesterol Lag Time, min
PC/LysoPC
0h 2h 4h
Copper oxidation
Control 26.8 116.2610.5 21.366.7 14.861.2 8.862.9
Diacyl PE enrichment
Low 26.3 114.3611.6 22.465.9 14.264.1 8.263.6
Medium 25.1 115.267.5 21.960.7 13.664.8 6.963.2
High 25.7 110.468.4 20.863.1 14.363.2 7.661.8
Plasmenylethanolamine enrichment
Low 30.7 125.667.3* 21.662.4 16.560.9* 10.761.6*
Medium 32.9 130.4612.8* 22.865.0 16.664.1 12.262.5†
High 37.5 139.2611.4† 21.461.9 17.663.4* 13.163.2†
AAPH oxidation
Low diacyl PE enrichment 26.3 zzz 22.465.9 13.862.3 8.162.4
Low plasmenylethanolamine enrichment 30.7 zzz 21.662.4 16.263.1* 11.061.4†
LDL from normolipidemic individuals was enriched in vitro with 3 different amounts of plasmenylethanolamine or diacyl PE as
described in Methods. Subsequently, the modified particles were oxidized with CuCl2 (1.67 nmol/ml) for maximally 4 h and the lag
time values measured. The PC/lysoPC ratios were determined as described in the legend to Figure 2. In some cases, the lipoproteins
were oxidized with AAPH (2 mmol/mL) instead of copper under otherwise identical experimental conditions. Mean values are from a
total of 4 or 5 determinations from 2 or 3 different lipoprotein preparations.
*P,0.05, †P,0.005 vs the same parameter of comparable LDL enrichment with diacyl PE.
2436 Arterioscler Thromb Vasc Biol. October 1999which is .10 times higher than that of the LDL particles, is
augmented after LDL apheresis.49 The enhanced delivery of
erythrocyte-derived plasmalogen phospholipids to the LDL
could contribute to the increase in LDL plasmalogen contents
after apheresis. The steeper plasmalogen gradient between
red blood cells and LDL induced by the rapid fall in LDL
concentrations might favor such an enhancement of plas-
malogen transfer.
LysoPC was previously reported to mediate the athero-
genic effects of in vitro–oxidized LDL, including the impair-
ment of endothelium-dependent vasodilation,50 the enhanced
adhesion of monocytes to the endothelium,38 and the in-
creased expression of endothelial growth factors.51 After LDL
apheresis, the endothelium-dependent vasodilation was found
to be ameliorated,12,52,53 and the adhesion of monocytes to the
endothelium was observed to be diminished.13,14 On the basis
of the results of the present study, these earlier findings might
be partially explained by the diminished lysoPC contents of
the particles (Table 2). The reasons for the increased PC/
lysoPC ratios after apheresis are unknown. It is unlikely that
the enhanced oxidative resistance of LDL after the apheresis
might play a prominent causal role, because there was no
correlation between this ratio and the duration of the lag time
(see Results). Therefore, other factors may be relevant, such
as alterations in the activities of enzymes known to remodel
LDL-associated PC (eg, lecithin:cholesterol acyltransferase).
In summary, the close associations between the LDL
contents of plasmalogen phospholipids and the duration of
the lag time observed in the present investigation indicate that
plasmalogens are of considerable relevance for the resistance
of LDL to copper oxidation. The diminished oxidizability of
the LDL after LDL apheresis is suggested to contribute to the
beneficial effects of the procedure on endothelial dysfunction
and the prevention of coronary artery disease.
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